Stocks Health care TRVI
NASDAQ · Health careTrevi Therapeutics, Inc. (TRVI)
It posted a net loss of $51.1M. In fiscal 2025 capital spending exceeded operating cash flow by $42.1M. At June 30, 2026 it held $54.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Trevi Therapeutics, Inc. does
Trevi Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TRVI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$42.8M | -$0.32 | -$42.1M |
| 2024 | n/a | -$47.9M | -$0.47 | -$38.3M |
| 2023 | n/a | -$29.1M | -$0.29 | -$31.8M |
| 2022 | n/a | -$29.2M | -$0.45 | -$28.3M |
| 2021 | n/a | -$33.9M | -$1.49 | n/a |
| 2020 | n/a | -$32.8M | -$1.81 | -$29M |
Latest SEC filings
What Trevi Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- June 4, 2026
- May 7, 2026Activist stake changed SCHEDULE 13D/A
- May 6, 2026Passive stake changed SCHEDULE 13G/A
- May 5, 2026Quarterly report 10-Q · period to March 31, 2026
- May 5, 2026
- April 21, 2026Proxy statement DEF 14A
Questions about TRVI
What does Trevi Therapeutics, Inc. do?
Trevi Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TRVI.
Is Trevi Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $51.1M.
When did Trevi Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 17, 2026.
Similar companies
Follow TRVI
Get an email when Trevi Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TRVI: get an email when it filesWhere the numbers come from
Financial figures are the values Trevi Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.